References
- Visco C, Barcellini W, Maura F, et al. Autoimmune cytopenias in chronic lymphocytic leukemia. Am J Hematol 2014; 89: 1055–1062.
- Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008: 450–456.
- Hodgson K, Ferrer G, Montserrat E, et al. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica 2011; 96: 752–761.
- Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013; 122: 2539–2549.
- Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010; 107: 13075–13080.
- Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213–223.
- Montillo M, O’Brien S, Tedeschi A, et al. Autoimmune hemolytic anemia and immune mediated thrombocytopenia in the phase III RESONATETM study of ibrutinib vs ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, including a case report. Blood 2014; 124: 5654.
- Rogers KA, Woyach JA, Andritsos LA, et al. Incidence of autoimmune cytopenias (AIC) in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) patients (pts) treated with ibrutinib. Blood 2014; 124: 1997.
- Manda S, Dunbar N, Marx-Wood CR, et al. Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia. Br J Haematol 2015; 170: 734–736.
- Hodskins J, Houranieh J, Fleischman RA. Ibutinib-associated autoimmune hemolytic anemia in CLL. Blood 2014; 124: 5671.